PharmaPoint: Alzheimer’s Disease – Global Drug Forecast and Market Analysis to 2026

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Alzheimer’s disease (AD) is a progressive neurodegenerative disease that is characterized by impaired memory and thinking (known as dementia), and functional decline. With a rapidly accelerating worldwide prevalence, there is a growing societal pressure for curative treatment for AD patients. The burden of AD encompasses clinical burden to patients as well as economic burden to payers and patients and caregiver burden, adding to the urgent need for improved AD therapy. Significant efforts are being made to develop a new treatment for AD, as current pharmacologic management is known to only provide a temporary improvement in symptoms.
 
GlobalData estimates the 2016 sales for AD at approximately $3.0B across the 7MM covered in this report.

The AD pipeline activity is strong, with twenty active Phase III (or Phase II/III) pipeline agents, most notable drug classes of which being passive immunotherapies and BACE inhibitors. These late-phase drugs also include those targeted for AD-linked agitation and cognitive impairments. Despite the fierce competition, GlobalData expects AD drug development to continue to see considerable struggles until reliable biomarkers and diagnostics are developed. Nevertheless, the treatment landscape of AD is expected to see a substantial change during the forecast period of 2016-2026.

Scope

Overview of AD: including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.

Annualized AD market revenue, cost of therapy per patient, and treatment usage patterns in three patient segments (including mild cognitive impairment, mild AD, moderate AD, and severe AD), forecast from 2016 to 2026.

Key topics covered: strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the AD therapeutics market

Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for AD therapy. The most promising candidate in Phase III (and Phase II/III) development is profiled.

Analysis of the current and future market competition in the global AD therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

The report will enable you to:

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

Develop business strategies by understanding the trends shaping and driving the global AD therapeutics market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global AD therapeutics market in the future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

AB Science
Abbvie
AC Immune
Acadia
Actinogen Medical
Adamas Pharmaceuticals
Allergan
Amgen
Archer Pharmaceuticals
AstraZeneca
Ausio Pharmaceuticals
Axovant
AZ Therapies
BioArctic NeuroScience AB
Biogen
Biogen
Bionomics
Boehringer Ingelheim
Boehringer Ingelheim
Bristol-Myers Squibb
Charsire Biotechnology Corp
Chugai
Cytos Biotechnology
Daiichi Sankyo
Eisai
Eli Lilly
Enzymotec
Glovia Co
Grifols
ImmunoBrain
Checkppoint
IntraCellular Therapies
Ionis
Janssen
Kyowa Hakko Kirin
Ligand
Lundbeck
Lupin
Mediti Pharma Inc
Merck & Co
Merz
Metabolic Therapy Inc
MorphoSys
Nature Cell
Nature Cell
Neurim Pharmaceuticals
Neurimmune
Neurotrope BioScience
Novartis
Ono Pharmaceutical
Orion Oyj
Otsuka
Pfizer
PharmatrophiX
Probiodrug AG
Proclara Biosciences
Purdue Pharma
QR Pharm
QR Pharma
Roche
Shionogi
Suven Life Sciences
T3D Therapeutics
Takeda
TauRx
Tetra Discovery Partners
Toyama Chemical
vTv Therapeutics
Zinfandel

Table of Contents

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Executive Summary

2.1 Alzheimer’s Market Forecast to See Double-Digit Sales Growth out to 2026

2.2 Allergan, Biogen, and Roche Are Forecast to Lead the AD Market in 2026

2.3 Lack of Treatments and Biomarkers Remain As Key Unmet Needs in the AD Market

2.4 Opportunities Remain for Disease-Modifying and Symptomatic Drugs Entering the AD Market

2.5 Twenty Promising Drugs in Phase II/III or Phase III of Development

2.6 What Do Physicians Think?

3 Introduction

3.1 Catalyst

3.2 Related Reports

4 Disease Overview

4.1 Etiology and Pathophysiology

4.1.1 Etiology

4.1.2 Pathophysiology

4.2 Disease Staging Systems

4.3 Symptoms

4.4 Prognosis

4.5 Quality of Life

5 Epidemiology

5.1 Disease Background

5.2 Risk Factors and Comorbidities

5.3 Global and Historical Trends

5.4 Forecast Methodology

5.4.1 Sources

5.4.2 Forecast Assumptions and Methods

5.4.3 Total Prevalent Cases of AD

5.4.4 Total Prevalent Cases of AD by Severity

5.4.5 Total Prevalent Cases of MCI

5.5 Epidemiological Forecast for AD (2016–2026)

5.5.1 Total Prevalent Cases of AD

5.5.2 Age-Specific Total Prevalent Cases of AD

5.5.3 Sex-Specific Total Prevalent Cases of AD

5.5.4 Total Prevalent Cases of AD by Severity

5.6 Epidemiological Forecast for MCI (2016–2026)

5.6.1 Total Prevalent Cases of MCI

5.6.2 Age-Specific Total Prevalent Cases of MCI

5.6.3 Sex-Specific Total Prevalent Cases of MCI

5.7 Discussion

5.7.1 Epidemiological Forecast Insight

5.7.2 Limitations of Analysis

5.7.3 Strengths of Analysis

6 Disease Management

6.1 Diagnosis Overview

6.1.1 Probable AD Dementia

6.1.2 Preclinical AD

6.1.3 MCI

6.2 Treatment Overview

6.3 Clinical Practice

6.3.1 Leading Prescribed Therapies

6.4 US

6.5 5EU

6.6 Japan

7 Competitive Assessment

7.1 Overview

7.2 Product Profiles – Major Brands

7.2.1 Aricept (Donepezil Hydrochloride)

7.2.2 Exelon (Rivastigmine, Rivastigmine tartrate)

7.2.3 Razadyne (Galantamine Hydrobromide)

7.2.4 Namenda (Memantine Hydrochloride)

7.2.5 Namzaric (Memantine and Donepezil Hydrochlorides)

7.3 Other Therapeutic Classes

8 Unmet Needs and Opportunity Assessment

8.1 Overview

8.2 Drugs with Disease-Modifying Mechanisms of Action

8.2.1 Unmet Need

8.2.2 Gap Analysis

8.2.3 Opportunity

8.3 Diagnosis in the Prodromal or Presymptomatic Stages

8.3.1 Unmet Need

8.3.2 Gap Analysis

8.3.3 Opportunity

8.4 Improved Control of Symptoms

8.4.1 Unmet Need

8.4.2 Gap Analysis

8.4.3 Opportunity

8.5 Easier Access to Treatment

8.5.1 Unmet Need

8.5.2 Gap Analysis

8.5.3 Opportunity

9 Pipeline Assessment

9.1 Overview

9.2 Clinical Trial Mapping

9.2.1 Clinical Trials by Class

9.3 Promising Drugs in Clinical Development

9.3.1 Biopharmaceutical Products

9.3.2 Gantenerumab

9.3.3 Crenezumab

9.3.4 Aducanumab

9.3.5 Flebogamma + Albutein

9.3.6 CAD106

9.3.7 Small Molecule

9.3.8 Verubecestat

9.3.9 Elenbecestat

9.3.10 Lanabecestat

9.3.11 JNJ-54861911

9.3.12 CNP520

9.3.13 Azeliragon

9.3.14 Pioglitazone

9.3.15 Nilvadipine

9.3.16 Intepirdine

9.3.17 ALZT-OP1

9.3.18 TRx-0237 (LMTX)

9.3.19 Brexipiprazole

9.3.20 Aripiprazole

9.3.21 AVP-786

9.3.22 ITI-007

9.3.23 Other Drugs in Development

10 Current and Future Players

10.1 Overview

10.2 Trends in Corporate Strategy

10.3 Company Profiles

10.3.1 Allergan

10.3.2 Lundbeck

10.3.3 Eisai

10.3.4 Pfizer

10.3.5 Novartis

10.3.6 Roche

10.3.7 Biogen

10.3.8 Eli lilly

10.3.9 Merck & Co.

10.3.10 AstraZeneca

10.3.11 Takeda

11 Market Outlook

11.1 Global Markets

11.1.1 Forecast

11.1.2 Drivers and Barriers – Global Issues

11.2 US

11.2.1 Forecast

11.2.2 Key Events

11.2.3 Drivers and Barriers

11.3 5EU

11.3.1 Forecast

11.3.2 Key Events

11.3.3 Drivers and Barriers

11.4 Japan

11.4.1 Forecast

11.4.2 Key Events

11.4.3 Drivers and Barriers

12 Appendix

12.1 Bibliography

12.2 Abbreviations

12.3 Methodology

12.3.1 Forecasting Methodology

12.3.2 Diagnosed Patients

12.3.3 Percent Drug-Treated Patients

12.3.4 Drugs Included in Each Therapeutic Class

12.3.5 Launch and Patent Expiry Dates

12.3.6 General Pricing Assumptions

12.3.7 Individual Drug Assumptions

12.3.8 Generic Erosion

12.3.9 Pricing of Pipeline Agents

12.4 Primary Research – KOLs Interviewed for This Report

12.4.1 KOLs

12.4.2 Payers

12.5 Primary Research – Prescriber Survey

12.6 About the Authors

12.6.1 Analyst

12.6.2 Therapy Area Director

12.6.3 Epidemiologist

12.6.4 Managing Epidemiologist

12.6.5 Global Director of Therapy Analysis and Epidemiology

12.6.6 Global Head and EVP of Healthcare Operations and Strategy

12.7 About GlobalData

12.8 Contact Us

12.9 Disclaime

Table

Table 1: MCI and AD: Key Metrics in the 7MM

Table 2: Three-Stage Classification of AD

Table 3: The Seven-Stage Reisberg Scale of AD

Table 4: Common Symptoms of AD.

Table 5: DSM-IV Criteria for the Diagnosis of Dementia

Table 6: NINCDS-ADRDA Criteria for the Diagnosis of AD

Table 7: Risk Factors and Comorbidities for AD

Table 8: 7MM, Total Prevalent Cases of AD, Both Sexes, Ages ≥60 Years, Selected Years 2016–2026.

Table 9: 7MM, Total Prevalent Cases of MCI, Both Sexes, Ages ≥60 Years, Selected Years 2016–2026.

Table 10: Commonly Used Diagnostic Guidelines for Alzheimer’s Disease

Table 11: Summary of NINCDS-ARDA Diagnostic Criteria for Alzheimer’s Disease

Table 12: Proposed NIA-AA Staging Classification for Preclinical AD

Table 13: NIA-AA Biomarker Criteria for MCI

Table 14: Commonly Used Treatment Guidelines for Alzheimer’s Disease in the 7MM

Table 15: Most Prescribed Drugs for AD by Class in the 7MM, 2016

Table 16: Most Commonly Prescribed Off-Label Drug Classes for AD, by Treatment Line, in the 7MM

Table 17: Country Profile – US

Table 18: Region Profile – 5EU, 2017

Table 19: Country Profile – Japan

Table 20: Leading Therapies in AD

Table 21: Product Profile – Aricept

Table 22: Efficacy Results for Aricept in Mild to Moderate AD

Table 23: Efficacy Results for Aricept in Moderate to Severe AD

Table 24: Efficacy Results for Aricept in Severe AD

Table 25: Aricept SWOT Analysis, 2017

Table 26: Product Profile – Exelon

Table 27: Efficacy Results for Exelon Capsule and Oral Solution in AD

Table 28: Efficacy Results for Exelon Patch in AD

Table 29: Adverse Events Occurring in at Least 2% of Patients and at a Higher Frequency than Placebo-Treated Patients

Table 30: Exelon SWOT Analysis, 2017

Table 31: Product Profile – Razadyne

Table 32: Efficacy Results for Razadyne in Probable AD

Table 33: Razadyne SWOT Analysis, 2017

Table 34: Product Profile – Namenda

Table 35: Efficacy Results for Namenda and Namenda XR in Alzheimer’s Disease

Table 36: Safety Results for Namenda and Namenda XR in Alzheimer’s Disease

Table 37: Namenda SWOT Analysis, 2017

Table 38: Product Profile – Namzaric

Table 39: Namzaric SWOT Analysis, 2017

Table 40: Summary of Minor Therapeutic Classes, 2017

Table 41: Comparison of Therapeutic Classes in Development for AD

Table 42: Product Profile – Gantenerumab

Table 43: Key Efficacy Results For Gantenerumab

Table 44: Pipeline Gantenerumab SWOT Analysis, 2017

Table 45: Ongoing Phase III Trials For Crenezumab, 2017

Table 46: Product Profile – Crenezumab

Table 47: Key Efficacy Data for Crenezumab

Table 48: Pipeline Crenezumab SWOT Analysis, 2017

Table 49: Product Profile – Aducanumab

Table 50: Key Efficacy Data for Aducanumab

Table 51: Key Safety Results For Aducanumab From Phase Ib PRIME Study

Table 52: Pipeline Aducanumab SWOT Analysis, 2017

Table 53: Product Profile – Flebogamma + Albutein

Table 54: Key Efficacy Data for Flebogamma + Albutein

Table 55: Key Safety Results For Flebogamma + Albutein From AMBAR (Interim Analysis)

Table 56: Flebogamma + Albutein SWOT Analysis, 2017

Table 57: Product Profile – CAD106

Table 58: CAD106 SWOT Analysis, 2017

Table 59: Product Profile – Verubecestat

Table 60: Verubecestat SWOT Analysis, 2017

Table 61: Product Profile – Elenbecestat

Table 62: Key Efficacy Data for Elenbecestat

Table 63: Elenbecestat SWOT Analysis, 2017

Table 64: Product Profile – Lanabecestat

Table 65: Key Efficacy Data for Lanabecestat

Table 66: Lanabecestat SWOT Analysis, 2017

Table 67: Product Profile – JNJ-54861911

Table 68: Key Efficacy Data for JNJ-54861911

Table 69: JNJ-54861911 SWOT Analysis, 2017

Table 70: Product Profile – CNP520

Table 71: Key Efficacy Data for CNP520

Table 72: CNP520 SWOT Analysis, 2017

Table 73: Product Profile – Azeliragon

Table 74: Azeliragon SWOT Analysis, 2017

Table 75: Product Profile – Pioglitazone

Table 76: Key Safety Results For Pioglitazone

Table 77: Pioglitazone SWOT Analysis, 2017

Table 78: Product Profile – Nilvadipine

Table 79: Nilvadipine SWOT Analysis, 2017

Table 80: Product Profile – Intepirdine

Table 81: Key Efficacy Results For Intepirdine

Table 82: Intepirdine SWOT Analysis, 2017

Table 83: Product Profile – ALZT-OP1

Table 84: ALZT-OP1 SWOT Analysis, 2017

Table 86: Product Profile – TRx-0237

Table 87: Key Efficacy Results for TRx-0237

Table 88: Key Safety Results For TRx-0237 from the Phase III TRx-237-005 Study

Table 89: TRx-0237 SWOT Analysis, 2017

Table 90: Product Profile – Brexipiprazole

Table 91: Key Efficacy Results For Brexipiprazole

Table 92: Brexipiprazole SWOT Analysis, 2017

Table 93: Product Profile – Aripiprazole

Table 94: Key Efficacy Results For Aripiprazole

Table 95: Key Safety Results For Aripiprazole

Table 96: Aripiprazole SWOT Analysis, 2017

Table 97: Product Profile – AVP-786

Table 98: AVP-786 SWOT Analysis, 2017

Table 99: Product Profile – ITI-007

Table 100: ITI-007 SWOT Analysis, 2017

Table 101: Drugs in Development for AD and AD-Related Symptoms, 2017

Table 102: Key Companies in the AD Market in the 7MM, 2017

Table 103: Allergan’s AD Portfolio Assessment, 2017

Table 104: Lundbeck’s AD Portfolio Assessment, 2017

Table 105: Eisai’s AD Portfolio Assessment, 2017

Table 106: Pfizer’s AD Portfolio Assessment, 2017

Table 107: Novartis’s AD Portfolio Assessment, 2017

Table 108: Roche’s AD Portfolio Assessment, 2017

Table 109: Biogen’s AD Portfolio Assessment, 2017

Table 110: Eli Lilly’s AD Portfolio Assessment, 2017

Table 111: Merck’s AD Portfolio Assessment, 2017

Table 112: AstrasZeneca’s AD Portfolio Assessment, 2017

Table 113: Takeda’s AD Portfolio Assessment, 2017

Table 114: AD Market – Global Drivers and Barriers, 2016–2026

Table 115: Key Events Impacting Sales for Alzheimer’s Disease in the US, 2016–2026

Table 116: AD Market – Drivers and Barriers in the US, 2016–2026

Table 117: Key Events Impacting Sales for AD in the 5EU, 2016–2026

Table 118: AD Market – Drivers and Barriers in the 5EU, 2016–2026

Table 119: Key Events Impacting Sales for AD in Japan, 2016–2026

Table 120: AD Market – Global Drivers and Barriers in Japan, 2016–2026

Table 121: Key Historical and Projected Launch Dates for AD

Table 122 : Key Historical and Projected Patent Expiry Dates for AD

Table 123: High-Prescribing Physicians (non-KOLs) Surveyed, by Country

Figures

Figure 1: Global Sales Forecast by Country for AD, 2016–2026

Figure 2: Company Portfolio Gap Analysis in AD, 2016–2026

Figure 3: Competitive Assessment of Late-Stage Pipeline Agents in AD, 2016–2026

Figure 4: AD Biomarker Tests by Pathophysiology

Figure 5: Dynamic Changes in AD Biomarker Over Time

Figure 6: 7MM, Age-Standardized Total Prevalence of AD (%), Ages ≥60 Years

Figure 7: 7MM, Age-Standardized Total Prevalence of MCI (%), Ages ≥60 Years

Figure 8: 7MM, Sources Used and Not Used, Total Prevalent Cases of AD

Figure 9: 7MM, Sources Used, Total Prevalent Cases of AD by Severity

Figure 10: 7MM, Sources Used, Total Prevalent Cases of MCI

Figure 11: 7MM, Age-Specific Total Prevalent Cases of AD, Both Sexes, 2016

Figure 12: 7MM, Sex-Specific Total Prevalent Cases of AD, Both Sexes, Ages >60 Years, 2016

Figure 13: 7MM, Total Prevalent Cases of AD by Severity, Both Sexes, Ages ≥60 Years, 2016

Figure 14: 7MM, Age-Specific Total Prevalent Cases of MCI, Both Sexes, 2016

Figure 15: 7MM, Sex-Specific Total Prevalent Cases of MCI, Both Sexes, Ages >60 Years, 2016

Figure 16: Disease Management Timeline For Alzheimer’s Disease

Figure 17: Unmet Need and Opportunity in AD, 2017

Figure 18: Overview of the Development Pipeline in MCI and AD

Figure 19 : Active Phase II and Phase III Clinical Trials in MCI and AD by Drug Class, 2017

Figure 20: Key Phase II/III and III Trials, Promising Pipeline Agents for MCI and AD, 7MM, 2016-2026

Figure 21: Key Phase III Trials of Promising Pipeline Agents for AD-Associated Agitation, 7MM, 2016–2026

Figure 22: Competitive Assessment of the Late-Stage Pipeline Agents for MCI and AD, 2017–2027

Figure 23: Clinical and Commercial Positioning of Gantenerumab

Figure 24: Clinical and Commercial Positioning of Crenezumab

Figure 25: Clinical and Commercial Positioning of Pipeline aducanumab

Figure 26: Clinical and Commercial Positioning of Pipeline Flebogamma + Albutein

Figure 27: Clinical and Commercial Positioning of Pipeline CAD106

Figure 28: Clinical and Commercial Positioning of Verubecestat

Figure 29: Clinical and Commercial Positioning of Elenbecestat

Figure 30: Clinical and Commercial Positioning of Lanabecestat

Figure 31: Clinical and Commercial Positioning of JNJ-54861911

Figure 32: Clinical and Commercial Positioning of CNP520

Figure 33: Clinical and Commercial Positioning of Azeliragon

Figure 34: Clinical and Commercial Positioning of Pioglitazone

Figure 35: Clinical and Commercial Positioning of Nilvadipine

Figure 36: Clinical and Commercial Positioning of Intepirdine

Figure 37: Clinical and Commercial Positioning of ALZT-OP1

Figure 38: Clinical and Commercial Positioning of TRx-0237

Figure 39: Clinical and Commercial Positioning of Brexipiprazole

Figure 40: Clinical and Commercial Positioning of Aripiprazole

Figure 41: Clinical and Commercial Positioning of AVP-786

Figure 42: Clinical and Commercial Positioning of ITI-007

Figure 43: Global Sales of AD Products, by Company, 2016 and 2026

Figure 44: Company Portfolio Gap Analysis in AD, 2016–2026

Figure 45: Allergan SWOT Analysis, 2017

Figure 46: Lundbeck SWOT Analysis, 2017

Figure 47: Eisai SWOT Analysis, 2017

Figure 48: Pfizer SWOT Analysis, 2017

Figure 49: Novartis SWOT Analysis, 2017

Figure 50: Roche SWOT Analysis, 2017

Figure 51: Biogen SWOT Analysis, 2017

Figure 52: Eli Lilly SWOT Analysis, 2017

Figure 53: Merck SWOT Analysis, 2017

Figure 54: AstraZeneca SWOT Analysis

Figure 55: Takeda SWOT Analysis, 2017

Figure 56: 7MM Sales Forecast by Country for AD, 2016 and 2026

Figure 57: Sales Forecast by Class for AD in the US in 2016 and 2026

Figure 58: Sales Forecast by Class for AD in the 5EU, 2016 and 2026

Figure 59: Sales Forecast by Class for AD in Japan in 2016 and 2026

Frequently asked questions

PharmaPoint: Alzheimer’s Disease – Global Drug Forecast and Market Analysis to 2026 thematic reports
Currency USD
$10,995

Can be used by individual purchaser only

$32,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

PharmaPoint: Alzheimer’s Disease – Global Drug Forecast and Market Analysis to 2026 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at PharmaPoint: Alzheimer’s Disease – Global Drug Forecast and Market Analysis to 2026 in real time.

  • Access a live PharmaPoint: Alzheimer’s Disease – Global Drug Forecast and Market Analysis to 2026 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.